What steps are companies taking to help curb AMR by manufacturing responsibly?

It is becoming increasingly clear that releasing antibiotic waste into the environment can drive antimicrobial resistance (AMR). In helping to curb this rapidly rising global health threat, pharmaceutical companies can ensure the production of their lifesaving antibiotics does not inadvertently contribute to drug resistance. A new report from the Foundation zeroes in on this issue, setting out three key areas pharmaceutical companies can focus on to ensure they limit AMR risk from manufacturing more effectively.